ProfileGDS5678 / 1455441_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 60% 63% 61% 62% 65% 34% 43% 58% 58% 59% 58% 62% 64% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6530160
GSM967853U87-EV human glioblastoma xenograft - Control 23.7714463
GSM967854U87-EV human glioblastoma xenograft - Control 33.6579361
GSM967855U87-EV human glioblastoma xenograft - Control 43.6822862
GSM967856U87-EV human glioblastoma xenograft - Control 53.8917165
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.853934
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0635743
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5049858
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4707858
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5243659
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4944858
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6874762
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8330964
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8072264